On March 26, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1st.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will highlight findings of the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer. Transgene will also discuss the potential of INTVs to reshape early-stage cancer treatment.
"We are delighted to share our positive data on our lead asset TG4050 with the scientific community", said Katell Bidet Huang, PhD, Head of Translational Medicine at Transgene.
"TG4050 is a highly innovative, AI-powered, immunotherapy designed individually for each patient, based on its tumor characteristics. In our Phase 1 trial, we were able to show that patients with resected head and neck cancer treated with our vaccine had developed new immune responses targeting preselected neoantigens present in the tumor cells, and TG4050-treated patients were all tumor-free 2 years after the start of their immune treatment. The comprehensive translational data generated to date supports our proposed mechanism of action and the ongoing Phase 2 trial. This technology could be applied across multiple solid tumors where significant unmet medical need remains.
With the myvac platform, Transgene will continue generating clinical data in patients with head and neck cancer and in an additional indication with the aim of preventing cancer relapse for patients at risk."
About the Oral Presentation:
Title: TG4050, an Individualized Neoantigen Therapeutic Vaccine in early-stage cancer treatment
Speaker: Dr Katell Bidet Huang, PhD, Head of Translational Medicine, Transgene
Session: Cancer & Immunotherapy Vaccines Conference – Early Development/Target selection & discovery
Date: April 1st, 2026, at 12:10 PM
(Press release, Transgene, MAR 26, 2026, View Source [SID1234663945])